Oral Oncology
Volume 45, Issue 1 , Pages 69-84 , January 2009

Is there a role for the Fas-/Fas-Ligand pathway in chemoresistance of human squamous cell carcinomas of the head and neck (SCCHN)?

  • Karl Christoph Sproll

      Affiliations

    • Department of Maxillo- and Plastic Facial Surgery, Westdeutsche Kieferklinik, Heinrich-Heine-University, Düsseldorf, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 211 81 0 40 92; fax: +49 211 81 1 88 77.
    • ,
  • Hilmar Balló

      Affiliations

    • Department of Otorhinolaryngology, Heinrich-Heine-University, Düsseldorf, Germany
    • ,
  • Thomas K. Hoffmann

      Affiliations

    • Department of Otorhinolaryngology, Heinrich-Heine-University, Düsseldorf, Germany
    • ,
  • Kathrin Scheckenbach

      Affiliations

    • Department of Otorhinolaryngology, Heinrich-Heine-University, Düsseldorf, Germany
    • ,
  • Ursula Koldovsky

      Affiliations

    • Department of Gynecology and Obstetrics, Heinrich-Heine-University, Düsseldorf, Germany
    • ,
  • Vera Balz

      Affiliations

    • Department of Otorhinolaryngology, Heinrich-Heine-University, Düsseldorf, Germany
    • ,
  • Dieter Hafner

      Affiliations

    • Department of Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany
    • ,
  • Uwe Ramp

      Affiliations

    • Department of Pathology, Heinrich-Heine-University, Düsseldorf, Germany
    • ,
  • Henning Bier

      Affiliations

    • Department of Otorhinolaryngology, Technical University, Munich, Germany

Received 4 February 2008 ,Revised 31 March 2008 ,Accepted 1 April 2008.

References 

  1. Vokes EE, Haraf DJ, Kies MS. The use of concurrent chemotherapy and radiotherapy for locoregionally advanced head and neck cancer. Semin Oncol. 2000;27(4 Suppl. 8):34–38
  2. Lavrik I, Golks A, Krammer PH. Death receptor signaling. J. Cell Sci. 2005;118(Pt 2):265–267
  3. Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407(6805):770–776
  4. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002;2(4):277–288
  5. Nagata S, Golstein P. The Fas death factor. Science. 1995;267(5203):1449–1456
  6. Krammer PH, Dhein J, Walczak H, Behrmann I, Mariani S, Matiba B, et al. The role of APO-1-mediated apoptosis in the immune system. Immunol Rev. 1994;142:175–191
  7. Gratas C, Tohma Y, Barnas C, Taniere P, Hainaut P, Ohgaki H. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res. 1998;58(10):2057–2062
  8. Gastman BR, Atarshi Y, Reichert TE, Saito T, Balkir L, Rabinowich H, et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res. 1999;59(20):5356–5364
  9. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993;75(6):1169–1178
  10. O’Connell J, Houston A, Bennett MW, O’Sullivan GC, Shanahan F. Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat Med. 2001;7(3):271–274
  11. O’Connell J, O’Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med. 1996;184(3):1075–1082
  12. Whiteside TL. Tumour-derived exosomes or microvesicles: another mechanism of tumour escape from the host immune system?. Br J Cancer. 2005;92(2):209–211
  13. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastas Rev. 1992;11(2):121–139
  14. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med. 1996;2(5):574–577
  15. Debatin KM, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene. 2004;23(16):2950–2966
  16. Muller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest. 1997;99(3):403–413
  17. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol. 1988;106(3):761–771
  18. Carey TE. Head and neck tumor cell lines. In:  Hay RJ,  Park JG,  Gadzar A editor. Atlas of human tumor cell lines. San Diego: Academic Press; 1994;p. 79–120
  19. Ballo H, Koldovsky P, Hoffmann T, Balz V, Hildebrandt B, Gerharz CD, et al. Establishment and characterization of four cell lines derived from human head and neck squamous cell carcinomas for an autologous tumor–fibroblast in vitro model. Anticancer Res. 1999;19(5B):3827–3836
  20. Pekkola-Heino K, Kulmala J, Klemi P, Lakkala T, Aitasalo K, Joensuu H, et al. Effects of radiation fractionation on four squamous cell carcinoma lines with dissimilar inherent radiation sensitivity. J Cancer Res Clin Oncol. 1991;117(6):597–602
  21. Zenner HP, Lehner W, Herrmann IF. Establishment of carcinoma cell lines from larynx and submandibular gland. Arch Otorhinolaryngol. 1979;225(4):269–277
  22. Bier H, Bergler W, Mickisch G, Wesch H, Ganzer U. Establishment and characterization of cisplatin-resistant sublines of the human squamous carcinoma cell line HLac 79. Acta Otolaryngol. 1990;110(5–6):466–473
  23. Hauser U, Balz V, Carey TE, Grenman R, Van Lierop A, Scheckenbach K, et al. Reliable detection of p53 aberrations in squamous cell carcinomas of the head and neck requires transcript analysis of the entire coding region. Head Neck. 2002;24(9):868–873
  24. Balz V, Scheckenbach K, Gotte K, Bockmuhl U, Petersen I, Bier H. Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res. 2003;63(6):1188–1191
  25. Stokes TA, Rymaszewski M, Arscott PL, Wang SH, Bretz JD, Bartron J, et al. Constitutive expression of FasL in thyrocytes. Sci Magaz. 1998;2015
  26. Fiedler P, Eibel H. Antibody mAb33 from transduction laboratories detects human CD95L in ELISA but not in immunoblots. Cell Death Differ. 2000;7(1):126–128
  27. Strater J, Walczak H, Hasel C, Melzner I, Leithauser F, Moller P. CD95 ligand (CD95L) immunohistochemistry: a critical study on 12 antibodies. Cell Death Differ. 2001;8(3):273–278
  28. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 1989;245(4915):301–305
  29. Schmitz I, Krueger A, Baumann S, Kirchhoff S, Krammer PH. Specificity of anti-human CD95 (APO-1/Fas) antibodies. Biochem Biophys Res Commun. 2002;297(3):459–462
  30. Kurihara N, Kubota T, Hoshiya Y, Otani Y, Ando N, Kumai K, et al. Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions. J Surg Oncol. 1996;62(2):135–138
  31. Hall SW, Strong JE, Broughton A, Frazier ML, Benjamin RS. Bleomycin clinical pharmacology by radioimmunoassay. Cancer Chemother Pharmacol. 1982;9(1):22–25
  32. Slater TF, Sawyer B, Straeuli U. Studies on succinate–tetrazolium reductase systems. III. Points of coupling of four different tetrazolium salts. Biochim Biophys Acta. 1963;77:383–393
  33. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1–2):55–63
  34. Hoffmann TK, Leenen K, Hafner D, Balz V, Gerharz CD, Grund A, et al. Antitumor activity of protein kinase C inhibitors and cisplatin in human head and neck squamous cell carcinoma lines. Anticancer Drugs. 2002;13(1):93–100
  35. Hafner D, Heinen E, Noack E. Mathematical analysis of concentration–response relationships. Method for the evaluation of the ED50 and the number of binding sites per receptor molecule using the logit transformation. Arzneimittelforschung. 1977;27(10):1871–1873
  36. Poch G, Londong W. Simple approach to assess potentiated drug combinations in clinical trials: studies with pirenzepine plus H2-receptor antagonists. Int J Clin Pharmacol Ther Toxicol. 1985;23(6):283–287
  37. Ossina NK, Cannas A, Powers VC, Fitzpatrick PA, Knight JD, Gilbert JR, et al. Interferon-gamma modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J Biol Chem. 1997;272(26):16351–16357
  38. Bagnoli M, Balladore E, Luison E, Alberti P, Raspagliesi F, Marcomini B, et al. Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment. Mol Cancer Ther. 2007;6(2):762–772
  39. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 1997;57(17):3823–3829
  40. Moers C, Warskulat U, Muschen M, Even J, Niederacher D, Josien R, et al. Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-gamma and cisplatin. Int J Cancer. 1999;80(4):564–572
  41. Mizutani Y, Wu XX, Yoshida O, Shirasaka T, Bonavida B. Chemoimmunosensitization of the T24 human bladder cancer line to Fas-mediated cytotoxicity and apoptosis by cisplatin and 5-fluorouracil. Oncol Rep. 1999;6(5):979–982
  42. Ramp U, Dejosez M, Mahotka C, Czarnotta B, Kalinski T, Wenzel M, et al. Deficient activation of CD95 (APO-1/Fas)-mediated apoptosis: a potential factor of multidrug resistance in human renal cell carcinoma. Br J Cancer. 2000;82(11):1851–1859
  43. Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, et al. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res. 1997;57(9):1758–1768
  44. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med. 1989;169(5):1747–1756
  45. Lutz W, Fulda S, Jeremias I, Debatin KM, Schwab M. MycN and IFNgamma cooperate in apoptosis of human neuroblastoma cells. Oncogene. 1998;17(3):339–346
  46. Micheau O, Solary E, Hammann A, Dimanche-Boitrel MT. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem. 1999;274(12):7987–7992
  47. Utz PJ, Anderson P. Life and death decisions: regulation of apoptosis by proteolysis of signaling molecules. Cell Death Differ. 2000;7(7):589–602
  48. Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J Natl Cancer Inst. 1997;89(11):783–789
  49. Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med. 1998;188(11):2033–2045
  50. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 2002;416(6880):560–564
  51. Concin N, Hofstetter G, Berger A, Gehmacher A, Reimer D, Watrowski R, et al. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53–p73 cross-talk in vivo. Clin Cancer Res. 2005;11(23):8372–8383
  52. Muller M, Schilling T, Sayan AE, Kairat A, Lorenz K, Schulze-Bergkamen H, et al. TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ. 2005;12(12):1564–1577
  53. Gressner O, Schilling T, Lorenz K, Schulze Schleithoff E, Koch A, Schulze-Bergkamen H, et al. TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. Embo J. 2005;24(13):2458–2471

PII: S1368-8375(08)00101-2

doi: 10.1016/j.oraloncology.2008.04.003

Oral Oncology
Volume 45, Issue 1 , Pages 69-84 , January 2009

Article Tools

* Image Usage & Resolution